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BACKGROUND. Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous
smoking-related disease characterized by airway obstruction and inflammation. This
inflammation may persist even after smoking cessation and responds variably to
corticosteroids. Personalizing treatment to biologically similar “molecular phenotypes” may
improve therapeutic efficacy in COPD. IL-17A is involved in neutrophilic inflammation and
corticosteroid resistance, and thus may be particularly important in a COPD molecular
phenotype.
METHODS. We generated a gene expression signature of IL-17A response in bronchial
airway epithelial brushings (“BAE”) from smokers with and without COPD (n = 238), and
validated it using data from two randomized trials of IL-17 blockade in psoriasis. This IL-17
signature was related to clinical and pathologic characteristics in two additional human
studies of COPD: (1) SPIROMICS (n = 47), which included former and current smokers with
COPD, and (2) GLUCOLD (n = 79), in which COPD participants were randomized to
placebo or corticosteroids.
RESULTS. The IL-17 signature was associated with an inflammatory profile characteristic
of an IL-17 response, including increased airway neutrophils and macrophages. In
SPIROMICS the signature was associated with increased airway obstruction and functional
small airway disease on quantitative chest CT. In GLUCOLD […]
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Background: Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous smoking-55 
related disease characterized by airway obstruction and inflammation. This inflammation may 56 
persist even after smoking cessation and responds variably to corticosteroids. Personalizing 57 
treatment to biologically similar “molecular phenotypes” may improve therapeutic efficacy in 58 
COPD. IL-17A is involved in neutrophilic inflammation and corticosteroid resistance, and thus 59 
may be particularly important in a COPD molecular phenotype.  60 
Methods: We generated a gene expression signature of IL-17A response in bronchial airway 61 
epithelial brushings (“BAE”) from smokers with and without COPD (n=238), and validated it 62 
using data from two randomized trials of IL-17 blockade in psoriasis. This IL-17 signature was 63 
related to clinical and pathologic characteristics in two additional human studies of COPD: (1) 64 
SPIROMICS (n=47), which included former and current smokers with COPD, and (2) GLUCOLD 65 
(n=79), in which COPD participants were randomized to placebo or corticosteroids.  66 
Results: The IL-17 signature was associated with an inflammatory profile characteristic of an IL-67 
17 response, including increased airway neutrophils and macrophages. In SPIROMICS the 68 
signature was associated with increased airway obstruction and functional small airway disease 69 
on quantitative chest CT. In GLUCOLD the signature was associated with decreased response 70 
to corticosteroids, irrespective of airway eosinophilic or Type 2 inflammation. 71 
Conclusion: These data suggest that a gene signature of IL-17 airway epithelial response 72 
distinguishes a biologically, radiographically, and clinically distinct COPD subgroup that may 73 
benefit from personalized therapy. 74 
Trial Registration: ClinicalTrials.gov NCT01969344 75 
Funding: Primary support from NIH/NHLBI. For others see below. 76 
 77 
Word Count: 242 78 
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Brief Summary (25 words): A COPD subgroup displays an enhanced IL-17A airway epithelial 79 
response associated with increased airway obstruction, neutrophilic inflammation, and a poor 80 























Personalizing treatment to “molecular phenotypes”, i.e. to subsets of patients with shared 102 
underlying biology, is an emerging strategy to guide therapeutic choices in chronic disease (1, 103 
2). In respiratory disease, this strategy has particularly gained traction in severe asthma where 104 
subgroups of patients with Type 2 and eosinophilic inflammation can be targeted using new 105 
biologics (1-4). Much of the inflammation in chronic respiratory disorders, however, does not 106 
respond to therapies directed against Type 2 inflammation. Identifying subgroups that display 107 
enhanced non-Type 2 inflammatory pathways may lead to the repurposing of available biologics 108 
indicated for other inflammatory disorders to target these subgroups. 109 
 110 
Chronic obstructive pulmonary disease (COPD) is a highly prevalent respiratory disease, most 111 
commonly associated with smoking. COPD is a major cause of morbidity and mortality 112 
worldwide for which few interventions have been found that prevent disease progression (5). 113 
Yet, molecular phenotyping has been less studied in COPD than in asthma and has focused on 114 
eosinophilic and type 2 inflammation based on the previous work in asthma (2). Type 2 115 
inflammation is likely relevant in only a minority of COPD patients (6). Nonetheless, this work 116 
suggests that biologically distinct COPD subgroups exist and are clinically relevant. COPD 117 
patients with high eosinophil counts or an airway epithelial genomic signature of Type 2 118 
inflammation are more likely to respond to corticosteroids, and potentially to biologics targeting 119 
eosinophils (6-9). These studies suggest the promise of molecular phenotyping in COPD, but 120 
responses beyond Type 2 inflammation require further investigation. 121 
 122 
The IL-17 family of cytokines includes six members that play various roles in mucosal host 123 
defense and chronic inflammation (10). IL-17A stimulates the airway epithelium to produce 124 
chemokines and other mediators which recruit and activate neutrophils and macrophages, cells 125 
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crucial to COPD pathogenesis (11). IL-17A is implicated in COPD-associated pathogenic 126 
responses, including emphysema, lymphoid neogenesis, corticosteroid resistance, dysbiosis, 127 
mucus hypersecretion, and ongoing inflammation despite smoking cessation (12-19). However, 128 
many of these responses have not been investigated in human studies. By identifying the 129 
COPD subgroup that manifests IL-17A associated inflammation (hereafter referred to as IL-17), 130 
we hypothesize that we can distinguish a corticosteroid-unresponsive subgroup that may benefit 131 
from anti-IL17 biologics. Anti-IL-17 biologics are now approved for the treatment of autoimmune 132 
diseases, specifically psoriasis and psoriatic arthritis, and are being studied in COPD (20, 21). 133 
Non-targeted trials of biologic therapies in COPD have failed to meet clinical endpoints, 134 
suggesting the importance of directing therapy to appropriate subgroups (22).  135 
 136 
Here we studied the transcriptional response of the airway epithelium to IL-17. We have found 137 
that direct measurement of interleukin proteins, including IL-17A, can be difficult in human blood 138 
and bronchoalveolar lavage fluid (23, 24). These challenges may contribute to the inconsistent 139 
evidence for IL-17A protein levels being increased in COPD (25-30). Conversely, airway 140 
epithelial cells have reproducible transcriptional responses to many interleukins. Thus our 141 
general strategy has been to assay this epithelial response, which we have validated for IL-13 142 
(24, 31, 32) and interferons (33).  143 
 144 
We examined a genomic signature of the airway epithelial IL-17 response in three separate 145 
human COPD studies in which bronchial airway samples were collected during bronchoscopy. 146 
We first fit the IL-17 genomic signature, generated using bronchial epithelial cells exposed to IL-147 
17, to a cross-sectional study of ever-smokers with and without COPD (Bronchial Airway 148 
Epithelial (BAE) dataset, n=237). We next established that the signature specifically identified 149 
IL-17 associated inflammation by determining its response to other airway epithelial adaptive 150 
immune responses (type 1 and 2) and to IL-17-directed biologic therapies in psoriatic skin 151 
7 
 
lesions. We then tested the associations between this IL-17 signature and clinical features in 152 
two independent COPD studies which collected rich phenotypic data (GLUCOLD: n= 79 and 153 
SPIROMICS: n=47, Study design in Figure 1). We hypothesized that our airway epithelial IL-17 154 
genomic signature would be increased in a COPD subset, and associated with distinct clinical, 155 
























Results  178 
Generation of an airway epithelial IL-17 associated gene expression signature in COPD 179 
We first characterized the airway epithelial response to IL-17 using whole transcriptome profiling 180 
of IL-17 versus vehicle control-stimulated human bronchial epithelial cell (HBEC) cultures grown 181 
at air liquid interface (ALI). The 100 genes most upregulated by log2 fold change in response to 182 
IL-17 were studied as candidate IL-17 signature genes.  183 
 184 
We examined these 100 genes in a previously generated bronchial airway epithelial 185 
transcriptome profiling dataset derived from bronchoscopic brushing samples from ever-186 
smokers with (n=85) and without COPD (n=152, Bronchial Airway Epithelial (BAE) dataset, 187 
demographics in Table 1). Candidate IL-17 signature genes were enriched amongst smokers 188 
with COPD compared to those without (mean of the zero-centered log2 gene expression in 189 
those with COPD=0.11 (±0.27) versus without= -0.60 (±0.19), p=6.10*10-6, Figure S1).  190 
 191 
Next, we generated a genomic signature of the IL-17 response specific to in vivo brushing 192 
samples from smokers by restricting the 100 gene signature identified in the culture model to 193 
those tightly correlated in the BAE dataset using an elastic net (34, 35). We took this additional 194 
step because cell culture models cannot optimally reproduce the complexity of the in vivo 195 
environment in which multiple mechanistic pathways impact gene expression, often with 196 
disparate affect. This signature refinement process is based on the premise that highly inter-197 
correlated genes are co-regulated by the same molecular processes, a premise also used by 198 
pathway analysis tools such as weighted gene co-expression analysis (36, 37). Starting with the 199 
100 candidate genes as predictors, elastic net regression with leave-one-out cross validation 200 
selected 10 genes highly correlated with a representative IL-17 related gene, CCL20, in the 201 
BAE dataset (Figure 2). We chose CCL20 a priori to guide the elastic net gene selection to 202 
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specifically identify an IL-17/CCL20-associated response. CCL20 was chosen for this role 203 
based on: 1) biological relevance, as an epithelial gene known to be the only ligand for CCR6, a 204 
chemokine receptor preferentially expressed by Th17 cells, and thus thought to be more specific 205 
for an IL-17 response as compared to other adaptive immune responses (38), and 2) statistical 206 
relevance, because it was highly upregulated (log2 fold change=2.92, FDR=0.0006) following IL-207 
17 stimulation in vitro. Importantly, this IL-17 associated gene was chosen to guide gene 208 
selection as our goal was to retain co-associated genes due to their potential biologic relevance, 209 
independent from outcomes of interest. We confirmed that the 10 genes selected by elastic net 210 
and CCL20 were all inter-correlated (Figure S2), verifying that the elastic net procedure 211 
removed loosely correlated genes. Nearly all of the 10 genes have previously been shown to be 212 
associated with IL-17 related inflammation (38-42). We thus used these 10 genes, along with 213 
CCL20, to construct a gene signature of airway epithelial response to IL-17 using the mean of 214 
their zero-centered log2 expression values. 215 
 216 
We confirmed that the genes selected for the signature are measuring an IL-17 response not 217 
just specific to CCL20 in two ways. First, we evaluated the correlation between our IL-17 218 
signature and a 5 gene airway epithelial IL-17 gene expression metric previously examined in 219 
asthma (39). In the BAE dataset the two signatures were well-correlated (ρ=0.51, p<2.2*10-16) in 220 
COPD participants, Figure S3, Table S1). The signatures were also correlated in an additional 221 
COPD dataset, GLUCOLD (demographics in Table 1), in which transcriptomic profiles from 222 
endobronchial biopsies were obtained from 79 participants with COPD (ρ=0.49, p=5.0*10-6, 223 
Figure S3, Table S1). Second, we repeated the elastic net procedure using SLC26A4, the gene 224 
most upregulated with IL-17 stimulation in cell culture also measured in the COPD array data 225 
(log2 fold change=8.51, FDR=0), to guide the elastic net. The SLC26A4-based signature 226 
incorporated 16 genes, 6 of which were also in the 11 gene CCL20-based signature, and was 227 
highly correlated with the CCL20-based signature in the BAE and GLUCOLD datasets (ρ=0.97 228 
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and p<2.2*10-16, ρ =0.87 and p<2.2*10-16, respectively, Figure S4, Table S1). Thus, removal of 229 
loosely associated genes from the 100 gene signature using CCL20 to guide the elastic net 230 
measured a response that does not appear to be exclusive to CCL20. However, we used the 231 
CCL20-based signature for our subsequent analyses as it had clear advantages over the 232 
others. The asthma signature was generated in a cell culture model and never fit to the in vivo 233 
environment. SLC26A4 is of unclear significance in IL-17 biology, and thus we considered the 234 
CCL20-based signature more biologically relevant.  235 
 236 
Validation of the IL-17 signature 237 
IL-17 related gene expression confirmed in an additional Airway Epithelial Culture Dataset  238 
We validated the association between the 10 genes selected by elastic net and IL-17 stimulation 239 
in another publicly available microarray dataset of HBECs grown at ALI and stimulated with IL-240 
17 for 24 hours (as opposed to the 7 day stimulation in our culture model) (GSE10240) (43). 241 
Although two of the 10 genes (SAA1 and SAA2) were poorly annotated on this array and could 242 
not be measured, the rest were significantly upregulated after IL-17 stimulation in this validation 243 
dataset (7 of 8 were within the top 50 genes by log2 fold change) despite differences in cytokine 244 
stimulation time. 245 
 246 
IL-17 related gene expression measures a response distinct from Type 1 and 2 immune 247 
responses  248 
Only three of the 11 IL-17 signature genes were significantly altered after HBECs at ALI were 249 
stimulated with interferon gamma, the main cytokine released from Th1 and Tc1 cells, and thus 250 
indicative of a Type 1 (T1) response. Two of the genes were repressed and one induced with an 251 
overall mean log2 fold change of -0.19 (Table S2). None of the genes were significantly 252 
upregulated in steroid-naïve mild-moderate asthmatics previously shown to have high type 2 253 
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(T2) gene expression (n=40) compared to asthmatics with low T2 expression (n=22) and 254 
healthy controls (n=43) (Table S3). 255 
 256 
Decreased IL-17 signature expression following IL-17 blockade in psoriatic lesions 257 
To further validate that our IL-17 signature reflects an IL-17 response, we examined it in two 258 
publicly available transcriptomic datasets of psoriatic skin lesions before and after controlled 259 
treatment with anti-IL-17 biologics.  260 
 261 
In the first dataset (GSE31652) (44), psoriatic skin lesion biopsies were taken at baseline and 262 
after two weeks of Ixekizumab, an anti-IL-17 monoclonal antibody (n=6), or placebo (n=4). All 263 
Ixekizumab-treated participants, but none of the placebo-treated, showed clinical improvement 264 
of at least 75% at 6 weeks. The skin IL-17 gene signature decreased over 2 weeks in lesions 265 
from Ixekizumab but not placebo-treated participants (p=0.003 for the interaction between 266 
treatment and time, Figure 3A and B). 267 
 268 
In the second dataset (GSE53552) (45), biopsies were taken from psoriatic skin lesions and 269 
matched non-lesional skin at baseline (n=25). Psoriatic lesions were then sampled over 6 270 
weeks after treatment with placebo (n=5) or a dose range of Brodalumab (n=20), an IL-17 271 
receptor α-blocking monoclonal antibody. Psoriatic lesions showed higher IL-17 signature 272 
expression compared to matched non-lesional skin (p=0.001, Figure 3C-F). The signature 273 
decreased over time in psoriatic lesions in those who received 350 or 700mg compared to 274 
placebo, but not in those who received 140mg (350mg: p=0.005 at 1 week, p=0.02 at 2 weeks, 275 
and p=0.12 at 6 weeks, 700mg: p=0.002 at 2 weeks and 0.0006 at 6 weeks for the interaction 276 
between treatment and time, Figure 3C-F). This was consistent with clinical treatment response 277 
(all placebo-treated and three of four 140mg-treated participants showed no clinical treatment 278 
response, all 700mg-treated and all but one 350mg-treated showed at least 70% clinical 279 
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improvement). The observation that our putative IL-17 signature tracked with clinical response 280 
to an IL-17 inhibitor in two psoriasis clinical trials provides independent confirmation of its value 281 
as a metric of IL-17 driven inflammation 282 
 283 
Characterization of the IL-17 signature in COPD transcriptional profiling datasets 284 
Cross-sectional characterization of an IL-17 gene signature in the BAE dataset 285 
In the BAE dataset, our 11 gene IL-17 signature was higher in former smokers (mean of the 286 
zero-centered log2 gene expression=0.29±0.46) compared to current smokers (-0.42±0.48, 287 
p<2.2*10-16, Figure 4A Table S4), and associated with older age (ρ=0.19, p=0.004). The 288 
signature was increased in COPD compared to ever-smokers without COPD (i.e. those with 289 
preserved lung function, 0.21±0.66 and -0.12±0.51 respectively, p=1.34*10-5), even after 290 
adjustment for smoking status and age (p=6.2*10-6). The signature was also higher with 291 
decreasing lung function (defined as the volume of air exhaled in the first second of a forced 292 
expiratory maneuver, or FEV1). Specifically, a higher gene signature was associated with lower 293 
FEV1 expressed as a percentage of the predicted value (FEV1% predicted) across all 294 
participants (1 unit increase in the IL-17 signature is associated with a 12 ml decrease in FEV1, 295 
p=1.40*10-5) and amongst only COPD participants (associated with a 5.5 ml decrease in FEV1, 296 
p= 0.04), suggesting an association with increasing COPD severity (Figure 4B).  297 
 298 
Cross-sectional characterization in GLUCOLD and SPIROMICS  299 
We next studied baseline clinical characteristics associated with the IL-17 signature in 300 
GLUCOLD and another COPD dataset, SPIROMICS (demographics in Table 1). GLUCOLD 301 
included endobronchial biopsy transcriptomic profiles from steroid-naïve participants with 302 
moderate to severe COPD (n=79). SPIROMICS included bronchial epithelial brushing profiles 303 
from ever smokers with mild to moderate COPD (n=47). Similar to the BAE dataset, in both 304 
13 
 
GLUCOLD and SPIROMICS the IL-17 signature was associated with increasing age (ρ=0.24, 305 
p=0.039 and ρ=0.20, p=0.046, respectively) and was higher in former compared to current 306 
smokers (p=2.42*10-6 and 1.35*10-5 respectively, Table S4). We performed subsequent 307 
analyses before and after adjustment for age and smoking status.  308 
 309 
Association with increased airway neutrophils and macrophages 310 
In GLUCOLD, the IL-17 signature was associated with increased airway biopsy neutrophil 311 
(p=6.41*10-5, Figure 5A) and macrophage counts (p=0.009, Figure 5B), but not eosinophils, 312 
mast cell counts, or our previously described T2 genomic score (Table 2). Tissue cell counts 313 
and the T2S score were not measured in SPIROMICS, but the T2S score was also not 314 
associated with the IL-17 signature in the BAE dataset (Table 2). The IL-17 signature was 315 
moderately associated with sputum neutrophil counts in both GLUCOLD (p=0.041, Figure 5C) 316 
and SPIROMICS (p=0.033, Figure 5D) although this did not stand up to multiple comparisons 317 
adjustment. There was no association with sputum eosinophil counts or any blood cell counts 318 
(Table 2).  319 
 320 
Association with airway obstruction 321 
Similar to the BAE dataset, in SPIROMICS we found that a higher IL-17 signature was 322 
associated with slightly greater airway obstruction in COPD (p=0.038 after adjustment for 323 
smoking and age, Figure S5, Table 3), although this was not significant after adjustment for 324 
multiple comparisons. In GLUCOLD we found a trend towards an association (p=0.06 before 325 
and p=0.12 after adjustment for smoking and age, Figure S5, Table 3).  326 
 327 
Association with CT measurements of functional small airway disease 328 
In SPIROMICS, we obtained inspiratory and expiratory quantitative Chest CT scans at study 329 
entry. We found that the IL-17 signature was associated with an increase in air-trapping in areas 330 
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devoid of emphysema (known as functional small airways disease (PRMfsad) by parametric 331 
response mapping (PRM) analysis (p=0.01, Figure 6A, Table 3) (46).The IL-17 signature was 332 
not associated with PRM-measured emphysema (PRMemph). However, almost all participants 333 
who underwent bronchoscopy had mild disease with very few displaying significant emphysema 334 
(Figure 6B).  335 
 336 
Association with decreased response to inhaled corticosteroids in GLUCOLD 337 
Following baseline bronchoscopy in GLUCOLD, 49 participants with available baseline biopsies 338 
were randomized to treatment with 30 months of ICS-containing medication (n=33) or placebo 339 
(n=16). A higher baseline IL-17 signature was associated with lack of improvement in post-340 
bronchodilator FEV1 on ICS, whereas a lower IL-17 signature was associated with improvement 341 
in FEV1, as compared to placebo (p=0.028 for the interaction between treatment and time, 342 
Figure 7, Table 3). We identified 28% of GLUCOLD participants as having high IL-17 gene 343 
expression (“IL-17 high”) by cluster partitioning (31% of COPD participants over all three 344 
studies, including 33% of BAE and 34% of SPIROMICS participants, were “IL-17 high”, Figure 345 
S6). After categorization of participants based on this cluster partitioning, those with an “IL-17 346 
low” designation were more likely to respond to ICS with an improvement in lung function while 347 
“IL-17 high” was associated with lack of response to ICS at 30 months (p=0.047 for the 348 
interaction between IL-17 status and percent change in FEV1 after ICS compared to placebo).  349 
We found that a high IL-17 signature is specific but not sensitive for steroid unresponsiveness. 350 
Using the dichotimization into IL-17 high and low by cluster partitioning the specificity for steroid 351 
unresponsiveness was 75% (Table S5). When the IL-17 high group is restricted to a slightly 352 
higher cut-off at the top quartile of IL-17 signature values, the specificity increases to 94% 353 
(Table S6). 354 
  355 
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The association between the IL-17 signature and change in FEV1 amongst ICS-treated 356 
participants was not due to those participants with low IL-17 signature expression reciprocally 357 
exhibiting high Type 2 inflammation. The significance of the relationship between the IL-17 358 
signature and ICS response persisted even after we adjusted for markers of steroid-responsive 359 
Type 2 inflammation using either airway tissue eosinophils (p=0.027) or our previously identified 360 
airway epithelial genomic signature of Type 2 inflammation (p=0.018, Figure S7, Table 3) (6). 361 
The association also does not appear to be explained by IL-17 inflammation simply reflecting 362 
tissue neutrophils or macrophages as adjustment for neutrophil or macrophage counts in the 363 
model also did not change the relationship between the IL-17 signature and ICS response 364 
(p=0.016 and 0.030, respectively, Table 3).  365 
 366 
The IL-17 signature alone explained 23% of the variation in change in FEV1 with corticosteroids 367 
(r2=0.23, Table 3). As expected given the low sensitivity of the IL-17 signature for steroid 368 
unresponsiveness, the Area Under the Receiver Operator Characteristic Curve (AUC) was 369 
modest (63%, Figure S8). However, there were no significant associations between other 370 
biomarkers of inflammation (including sputum and blood cell counts) and change in FEV1 in ICS 371 
versus placebo-treated participants after adjustment for age and smoking status. Furthermore, 372 
the AUCs for these other potential biomarkers (sputum eosinophils: 51%, blood eosinophils: 373 
55%, sputum neutrophils: 52%, blood neutrophils: 45%) suggest that they lack any predictive 374 
power for corticosteroid responsiveness in this dataset (supplemental Figure S8). Although 375 
limited by small sample size, these proof-of-concept analyses suggest that our airway epithelial 376 
signature of IL-17 response in COPD may mark FEV1 response to ICS better than easily 377 






Discussion  382 
In this study, we used three complementary human COPD studies to characterize the clinical 383 
significance of the airway epithelial response to IL-17 in COPD. We showed that a signature of 384 
IL-17 associated airway inflammation is upregulated in a subset of participants with COPD (31% 385 
across studies), and is associated with distinct inflammatory, physiologic, and clinical features. 386 
Increases in this signature are associated with an inflammatory profile characteristic of an IL-17 387 
response, including increased airway neutrophils and macrophages but not eosinophils, Type 2 388 
markers, or Type 1 gene expression. Decreases in the signature occur in response to 389 
therapeutic blockade of IL-17 in psoriatic skin lesions, and this response corresponds to clinical 390 
improvement in that disease. In COPD, the signature is further associated with more severe 391 
airway obstruction and a novel CT biomarker of functional small airway disease that is predictive 392 
of worsening airway disease over time (46, 47). Finally, higher IL-17 signature expression is 393 
associated with a lack of response to ICS in COPD, whereas low expression may identify those 394 
patients who benefit from ICS. This association does not simply appear to be due to reciprocal 395 
alterations in Type 2 inflammation as the interaction between our IL-17 signature and treatment 396 
was unaffected by adjustments for airway eosinophils or our Type 2 airway genomic signature. 397 
Thus, our findings suggest that enhanced IL-17 inflammation characterizes a distinct subset of 398 
COPD, and that identifying this subgroup may be important for therapeutic decisions.  399 
 400 
In COPD, chronic exposure to smoking, microbial insults, and recurrent mucosal injury may all 401 
contribute to immune activation with IL-17A producing T cells, supported by innate IL-17A 402 
producing cells (17). This likely contributes to ongoing neutrophilic inflammation and 403 
macrophage recruitment with subsequent airway remodeling and tissue destruction (48). We 404 
found that our IL-17 gene expression signature is associated with increases in airway 405 
neutrophils and macrophages, indicating an IL-17 response. It is related to worse clinical 406 
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outcomes across former and current smokers. These findings provide evidence for the 407 
contribution of IL-17 inflammation to COPD pathology despite smoking cessation. 408 
 409 
We found that the IL-17 response in COPD is heterogeneous, enhanced in a subgroup. Prior 410 
studies found variability in IL-17-related inflammation within COPD (13, 25-30), and our data 411 
suggest that this variability is clinically significant. Other studies have identified some 412 
characteristics of IL-17 associated inflammation in COPD including more severe obstruction, 413 
emphysema, and lymphoid neogenesis (13, 15). Here we comprehensively investigated the 414 
associations between IL-17 driven inflammation and COPD patient characteristics. In addition to 415 
an association with increased airway obstruction, we found associations with a novel CT 416 
biomarker of functional small airways disease and corticosteroid unresponsiveness. COPD 417 
phenotypes are heterogeneous and complex. Thus we hypothesize that multiple overlapping 418 
molecular phenotypes underlie the complex clinical phenotypes we observe in chronic airway 419 
diseases and that there will be an upper bound to the predictive power of any one biological 420 
pathway (33, 49). However, a strength here is that we observe correlations that are reproducible 421 
across our transcriptional datasets (for associations with neutrophils and FEV1). 422 
 423 
We had hypothesized that the IL-17 signature would be associated with increased emphysema, 424 
as found in a previous study (13). We evaluated this using the recently developed PRM CT 425 
analysis method (46). By matching inspiratory and expiratory scans, PRM improves the ability to 426 
distinguish emphysema from functional small airway disease, both of which are associated with 427 
low radio-density lung regions on expiration (i.e. air trapping). Our IL-17 signature is associated 428 
with PRMfsad but not PRMemph in SPIROMICS. As the participants generally had mild to 429 
moderate disease with minimal emphysema, the lack of association with PRMemph is not 430 
surprising. The association with PRMfsad is of interest as the small airways are likely the main 431 
site of airway inflammation in COPD, and small airway disease is thought to precede 432 
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emphysema (50). Studies using PRM have supported these findings. PRMfsad is associated with 433 
more rapid FEV1 decline, particularly in mild to moderate disease (47). PRMfsad is also the 434 
greater contributor to radiographic abnormalities in mild to moderate COPD with both PRMfsad 435 
and PRMemph contributing in severe disease (46). Thus, an association between our IL-17 436 
signature and PRMfsad in mild to moderate COPD does not preclude an association with 437 
emphysema in more severe disease. In fact, it signifies an association with a more severe 438 
phenotype amongst participants with milder airway obstruction and suggests that IL-17 related 439 
inflammation may be a pathway on which to intervene to prevent the progression to emphysema 440 
and severe airway obstruction. 441 
 442 
Our IL-17 signature, when measured at baseline, is associated with a poor lung function 443 
response to corticosteroids at 30 months. This corticosteroid responsiveness is not simply due 444 
to participants with low IL-17 signature expression exhibiting low neutrophil counts or 445 
reciprocally exhibiting high Type 2 inflammation. In murine models, Th-17 cell-mediated airway 446 
inflammation has been shown to be corticosteroid resistant, in contrast to Th2 cell-mediated 447 
inflammation (51). Here we show the association between an IL-17 inflammatory signature and 448 
corticosteroid unresponsiveness for the first time in a longitudinal randomized controlled trial in 449 
humans. Many patients with COPD do not respond to corticosteroids, and ICS are only 450 
indicated in exacerbation-prone symptomatic COPD. However, corticosteroids are still used 451 
broadly despite possible increases in adverse outcomes such as pneumonia (52). The 452 
corticosteroid unresponsiveness finding suggests that a more easily measurable surrogate for 453 
our IL-17 signature could serve as a biomarker for therapeutics in COPD. While it may be useful 454 
to predict who will not respond to corticosteroids, it may be even more useful to predict who will 455 
respond to therapies targeting IL-17 or associated inflammatory pathways as we found in 456 




Our study relied on the airway epithelial gene expression response to IL-17, where the cytokine 459 
induces a major effect, and the first line of defense against injury to the lung. Other studies have 460 
relied on cell counts or immunoreactivity which are poorly correlated in the human lung (13). 461 
Additionally, Th17 cells display a high level of plasticity, and are thus more unstable than Th1 or 462 
Th2 cells (53), suggesting cell numbers may not represent cytokine response. Data is also 463 
conflicting on whether IL-17+ cell counts are elevated in COPD and related to key pathologic 464 
characteristics such as airway neutrophilia (28, 29). We, however, show that IL-17 signature 465 
genes are not only upregulated in two separate experiments in which HBE cells were stimulated 466 
with IL-17, but that our signature is associated with increases in airway neutrophils as well. We 467 
also show that our signature is decreased in response to IL-17 blocking agents in psoriatic skin 468 
lesions but distinct from airway epithelial Type 1 and 2 responses, further indicating that we are 469 
marking an IL-17 specific epithelial response. 470 
 471 
We acknowledge that fitting our IL-17 signature to CCL20 could have limited its generalizability. 472 
However, the signature generalized well in that: 1) it was highly correlated with two other IL-17 473 
gene signatures (a signature previously studied in asthma (39) and a signature fit to SLC26A4, 474 
the most significantly upregulated gene in our IL-17 stimulated HBE culture experiments) and 2) 475 
our IL-17 signature was responsive to anti-IL17 therapy and reflective of clinical response in 2 476 
randomized controlled trials in psoriasis. The advantage of fitting this gene signature to CCL20 477 
is that it improved its “fit” to a more complex in vivo tissue environment rather than a simple cell 478 
culture model. In a COPD patient this complex environment may be further compounded by 479 
multiple airway insults (e.g. smoking, microbial colonization, exacerbations, medications) that 480 
are not modelled well in culture. By retaining only tightly inter-correlated genes, a well-481 
established method for identifying genes in the same molecular pathway (36, 37), we removed 482 




Our study has some potential limitations. For instance, some analyses were cross-sectional, 485 
and those analyses can only show associations, not causality. Our longitudinal analyses were 486 
limited by sample size. Thus, while we did find a strong association between our IL-17 signature 487 
and lack of response to inhaled steroids over 30 months, an assessment of the predictive power 488 
of the signature for corticosteroid responsiveness was quite limited. Furthermore, our definitions 489 
of “high” and “low” for the IL-17 signature are highly dependent on the population in which they 490 
were developed. Therefore, further studies will be needed to determine if the signature could be 491 
used as a biomarker for steroid unresponsiveness, and to determine the best cut-off for IL-17 492 
“high” and “low”. We were also not powered to study the association between the signature and 493 
exacerbation rates, which will be important to study in relation to therapeutic response. It was 494 
not within the scope of this paper to identify the cause of the increased IL-17 response. We do, 495 
however, see associations in current and former smokers, suggesting that more than just smoke 496 
exposure is playing a role. The contributions of stimuli, such as alterations in the microbiome or 497 
autoimmunity, to enhanced IL-17 related gene expression will require further study. 498 
Furthermore, COPD phenotypes are heterogeneous and complex, and thus we hypothesize that 499 
multiple overlapping molecular phenotypes underlie the complex clinical phenotypes we 500 
observe in chronic airway diseases. Finally, future work will be needed to identify surrogate 501 
biomarkers in more easily obtained specimens than airway brushings. This is similar to the 502 
approach we took in our asthma studies in which we initially identified a Type 2 high asthma 503 
molecular phenotype based on airway gene expression, and then expanded this work to identify 504 
the best associated biomarkers (periostin, eosinophils, FeNO). 505 
 506 
In summary, we show here that a signature of IL-17 associated airway inflammation is 507 
upregulated in approximately a third of COPD participants and is associated with distinct 508 
inflammatory, physiologic, and clinical features. Our findings suggest that the IL-17 signature 509 
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defines a molecular COPD phenotype that responds poorly to corticosteroid therapy, and which 510 



























Materials and Methods 536 
Transcriptomic Datasets: 537 
Eight transcriptomic datasets were used for these analyses. 538 
1. UCSF Human bronchial epithelial cell (HBEC) culture dataset: 539 
Human bronchial epithelial cells obtained from the proximal airways of 6 lung donors 540 
rejected for transplant (5 without airway disease, 1 with asthma) were grown to confluence 541 
in an air-liquid interface culture (ALI) for 28 days as described previously (54). Some 542 
cultures were stimulated with IL-17A (10 ng/mL) for the final 7 days of culture or interferon 543 
gamma (IFNγ, 10 ng/mL) for the final 24 hours of culture. Matched cultures maintained in 544 
media without cytokine over the same time period were used as controls. Cultured cells 545 
were then harvested and underwent RNA isolation using the Qiagen miRNeasy kit (Qiagen 546 
Inc., Valencia, CA) as per manufacturer’s protocol. RNA quality and quantity were assessed 547 
using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) and the 548 
NanoDrop Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE).  Library 549 
preparation and multiplexing were done using the Illumina TruSeq Stranded Total RNA with 550 
Ribo-zero Human/Mouse/Rat kit (Illumina Inc, San Diego, CA) as per manufacturer’s 551 
protocol at the UCSF Sandler Genomics Core Facility. 100 base pair paired-end sequencing 552 
was done on multiplexed samples via the Illumina HiSeq 2500 at the UCSF Genomics Core.  553 
 554 
2. Bronchial Airway Epithelial (BAE) dataset: Bronchial epithelial brushings obtained from 555 
6th-8th generation bronchi of former and current smokers with a range of lung function 556 
(COPD=85, no COPD=152) were previously profiled by Affymetrix (Santa Clara, CA) HG 1.0 557 
ST Arrays (55). Spirometry was done in all participants. Raw microarray files may be 558 
downloaded from the Gene Expression Omnibus (GEO, accession: GSE37147) (54). 559 




3. Validation HBEC culture dataset: Data were downloaded from GEO (GSE10240). Primary 562 
HBE cells provided by the Tissue Core Laboratory at the University of Pittsburgh or 563 
purchased from Cambrex (Lonza) were grown to confluence in ALI then stimulated apically 564 
and basolaterally with media control or IL-17A for 24 hours (3 replicates each) as previously 565 
described (43). Isolated RNA was profiled by Affymetrix HG U133A 2.0 Arrays.  566 
 567 
4. Asthma Dataset: Bronchial airway epithelial brushings obtained by bronchoscopy from 568 
steroid-naive subjects with mild to moderate asthma (n = 62) and control subjects without 569 
asthma (n = 43) were previously profiled by Affymetrix HG U133 plus 2.0 Arrays 570 
(GSE67472) (24). Inclusion/exclusion criteria for this study were previously published (24). 571 
Subjects with asthma were divided into Type 2-high and -low subgroups (n = 40 and 22, 572 
respectively) using a validated standardized mean expression level of POSTN, SERPINB2, 573 
and CLCA1 (24, 32). IL-17 associated genes were evaluated amongst those differentially 574 
expressed between Type 2-high asthma compared to Type 2-low asthma and healthy 575 
controls. 576 
 577 
5. Ixekizumab Psoriasis Dataset: Data were downloaded from GEO (GSE31652). Biopsies of 578 
psoriatic skin lesions were taken at baseline and after treatment with two weeks of 579 
Ixekizumab (n=6) or placebo (n=4) and previously profiled by Affymetrix HG U133A 2.0 580 
Arrays (44).  581 
 582 
6. Brodalumab Psoriasis Dataset: Data were downloaded from GEO (GSE53552). Biopsies 583 
were taken from psoriatic skin lesions and matched non-lesional skin from 25 participants at 584 
baseline. The psoriatic lesions were then sampled over 6 weeks after treatment with 585 
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placebo (n=5) or a dose range of Brodalumab (140mg n=4, 350mg n=8, 700mg n=8). All 586 
samples were previously profiled by Affymetrix HG U133 plus 2.0 Arrays (45). 587 
 588 
7. Gronigen and Leiden Universities study of Corticosteroids in Obstructive Lung 589 
Disease (GLUCOLD) dataset: Endobronchial biopsies from steroid-naïve participants with 590 
moderate to severe COPD (n=79) were previously obtained by bronchoscopy and profiled 591 
by Affymetrix HG 1.0 ST Arrays (GSE36221) (56). Blood collection, sputum induction, and 592 
spirometry were done at the first study visit via previously described methods (57). A subset 593 
of these participants was randomized to receive 30 months of placebo (n=16) or ICS with or 594 
without long acting beta agonist (salmeterol, LABA) (n=33). Inclusion/exclusion criteria were 595 
previously published (57). 596 
 597 
8. Subpopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) 598 
dataset: A subgroup of participants in the SPIROMICS multi-center observational cohort 599 
study underwent research bronchoscopy. RNA was obtained from bronchial epithelial 600 
brushings from 3rd-4th generation bronchi of the right or left lower lobe of current and former 601 
smokers with mild to moderate COPD (n= 47). RNA was used for profiling IL-17-associated 602 
gene expression by two-step, nested-primer RT-qPCR as described previously (32). Primer 603 
and probe sequences are listed in Table S4. 604 
 605 
At least a 20 pack-year smoking history was required for inclusion, and participants were 606 
classified as former smokers after one year of smoking cessation.  Participants were 607 
classified as having COPD based on spirometry, performed before and after four inhalations 608 
each of albuterol (90μg dose per inhalation) and ipratropium (18μg dose per inhalation), 609 
using the GOLD staging system (58). Full inclusion/exclusion criteria are included in Table 610 




Blood collection, sputum induction, and CT scans were done at the first study visit. Sputum 613 
induction was performed as previously described (59). Parametric response mapping (PRM) 614 
of CT imaging was used to distinguish areas of normal lung (PRMnorm) from areas of 615 
functional small airways disease (PRMfsad) and emphysema (PRMemph) as previously 616 
described (46, 47). Briefly, PRM is a CT voxel-based imaging biomarker that utilizes 617 
dynamic image registration to spacially align paired inspiratory and expiratory scans. 618 
PRMfsad is defined as areas of lung that are >-950 Hounsfield Units (HU) on inspiration and 619 
<-856 HU on expiration. PRMemph is defined as areas of lung that are <-950 HU on 620 
inspiration and <-856 HU on expiration. PRMnorm is defined as areas of lung exceeding both 621 
thresholds on inspiration and expiration.   622 
 623 
Derivation of gene expression datasets: 624 
RNA-Seq (HBEC culture dataset): 625 
.fastq files were quality filtered and aligned to the human genome using STAR and the 626 
ENSEMBL GRCh38 genome build (60, 61). Read counts were normalized and differential 627 
expression analyses on matched samples were performed between 1) IL-17A stimulated 628 
samples and controls, and 2) IFNγ-stimulated samples and controls using the DESeq2 629 
package in R (62). Differential expression in DESeq2 is carried out using generalized linear 630 
models following a negative binomial distribution. Results were trimmed to transcripts 631 
indexed in the HGNC database and with a Ensembl gene biotype label of “protein_coding”. 632 
Multiple comparisons corrections were done using False Discovery Rate by the Benjamini-633 
Hochberg method (63).  634 
 635 
Microarray (BAE, Asthma, GLUCOLD, Ixekizumab, and Brodalumab datasets): 636 
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Each microarray dataset independently underwent background adjustment (without the use 637 
of mismatch probes), quantile normalization, and probe summarization using the RMA 638 
algorithm (affy package, Bioconductor, R) (64, 65). Entrez gene custom chip definition files 639 
available for the appropriate microarray for each dataset at 640 
http://brainarray.mbni.med.umich.edu were used for annotation. Batch effect was minimized 641 
using Combat when appropriate (66). 642 
 643 
qPCR (SPIROMICS dataset): 644 
Data were normalized to the mean of PPIA, RPL13A, ACTB, and DNAJA1, determined using 645 
the SLqPCR package in R, as described previously (32, 67).  646 
 647 
Derivation of the IL-17 genomic signature 648 
An IL-17 genomic signature specific to bronchial epithelial brushings from smokers was 649 
generated using elastic net regression for feature selection in the BAE dataset. The 100 genes 650 
most up-regulated in ALI models after IL-17A stimulation were used as candidate predictor 651 
variables (“features”). Genes highly correlated with a representative IL-17 gene, CCL20, were 652 
selected as features for inclusion into the IL-17 signature using elastic net regression via the 653 
glmnet package in R with alpha=0.75 and leave-one-out cross-validation (68). Alpha was 654 
selected at just below one to maximize sparsity (and thus limit feature selection) while allowing 655 
for selection of closely correlated genes. CCL20 and the 10 genes selected by elastic net 656 
regression were used for generation of the IL-17 signature. The mean of the zero-centered log2-657 
scale gene expression values of these 11 genes was used as the IL-17 airway epithelial 658 
signature metric, a previously validated method (33, 39). To confirm that our IL-17 signature 659 
was not just specific to CCL20, two alternative IL-17 signatures were generated. One was 660 
generated using the above procedure with SLC26A4, the most upregulated gene following IL-17 661 
stimulation in cell culture also measured in the COPD array data, guiding the elastic net. The 662 
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other was an IL-17 signature previously studied in asthma and was generated in the same way 663 
as previously reported, using the mean value of the zero-centered gene expression of five IL-17 664 
associated genes (39).  665 
 666 
For the Ixekizumab and Brodalumab studies, four genes were excluded prior to deriving the IL-667 
17 signature metric: two genes that were poorly annotated in the microarray platform used 668 
(SAA1, SAA2), and two genes that were not expressed above background (CSF3, MTNR1A1) 669 
in these skin biopsies. As there was 100% concordance between the two psoriasis studies on 670 
genes not expressed above background, we concluded that these genes were poorly expressed 671 
in the resident skin cells. We did not, however, change the signature in any way based on 672 
knowledge of the genes or relevance in psoriasis. The IL-17 skin signature was thus derived 673 
using the mean value of the zero-centered log2-scale gene expression values of the remaining 674 
seven genes (CCL20, SLC26A4, TNIP3, CXCL3, CXCL5, CXCL6, and VNN1). 675 
 676 
Statistical analyses of the IL-17 genomic signature 677 
All regression analyses were performed using the limma package in R (69). For cross-sectional 678 
analyses of the associations between the IL-17 signature and clinical variables (in the BAE, 679 
GLUCOLD, and SPIROMICS datasets) linear or logistic regression were used, as appropriate. 680 
Analyses were done before and after adjustment for age and smoking status. Race, gender, pack-681 
years, and inhaled corticosteroid use were evaluated as potential confounders as well. These 682 
variables were, however, left out of the final models as they were not significantly associated with 683 
IL-17 signature expression, and did not significantly alter the relationships between the IL-17 684 
signature and outcomes beyond adjustments for age and smoking status. Data was transformed 685 
when necessary for normal distribution. A P value less than 0.05 was considered significant. 686 
However, multiple hypothesis testing was done using a false discovery rate when appropriate 687 
(63).  For the Ixekizumab and Brodalumab studies mixed effects models were used to relate the 688 
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IL-17 signature (as the outcome variable) to the interaction between treatment and time (fixed 689 
effects) across participants (random effect).  For longitudinal analyses in GLUCOLD the 690 
interaction between treatment (ICS or placebo) and the baseline IL-17 signature was related to 691 
change in FEV1 over 30 months. The ICS and ICS + long acting beta agonist groups were 692 
combined to improve power as the long-term effects in these groups were comparable. In 693 
secondary analyses, the interactions between the IL-17 score and A) tissue eosinophils, B) our 694 
previously generated metric of Type 2 inflammation (the T2S score), or C) tissue neutrophils were 695 
related to change in FEV1 over 30 months amongst those GLUCOLD participants that received 696 
ICS (6).   697 
 698 
Clustering 699 
All clustering analyses were performed using euclidean distance with average linkage as the 700 
distance metric. The NbClust package (R, bioconductor) was used to determine the best 701 
participant clustering of the IL-17 signature genes, based on a majority vote of 30 indices that 702 
evaluate partitioning (70). NbClust deals with the inherent variability in the many indices 703 
available to determine the optimal number of clusters by requiring a consensus vote amongst 704 
these indices on best partitioning. Participants with relatively high expression who clustered 705 
separately from the majority of participants were considered “IL-17 High”. Prior to determining 706 
the best number of partitions the datasets were first stratified by smoking status given the large 707 
effect of smoking on gene expression. Differences amongst indices in deciding best clustering 708 
were generally due to separation of those with “IL-17 High” expression into one or more 709 
categories, while those with low expression clustered together. The exception were two 710 
participants in the SPIROMICS dataset with low expression that were partitioned into their own 711 
groups. Six of 35 participants with relatively high IL-17 gene expression in the BAE dataset, 3 of 712 
23 participants in the GLUCOLD dataset, and 5 of 18 participants in the SPIROMICS dataset 713 
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were partitioned out as the highest for IL-17 expression. For simplicity, all IL-17 high, including 714 
these highest participants, were grouped together. 715 
 716 
The IL-17 signature was then discretized into two categories: “IL-17 high” and “IL-17 low” using 717 
two different methods to use as a categorical predictor for longitudinal analyses in GLUCOLD. 718 
First, discretization was based on the best partitioning decided by NbClust, and then, 719 
alternatively based on the top quartile of signature expression. Ten percent of samples with IL-720 
17 signatures closest to the partition were removed prior to discretization to diminish overlap. 721 
 722 
Study Approval 723 
The included human studies were all approved by the institutional review boards at the 724 
institutions involved in sample and data collection. All participants provided written informed 725 
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Longitudinal characterization:  
Figure 1. Study Design. Abbreviations: BEC: Bronchial Epithelial Cell, ALI: air-liquid interface,
RNA-Seq: RNA Sequencing, BAE: Bronchial Airway Epithelial, T1: Type 1 Inflammation, 















Figure 2. Hierarchical clustering of the 11 IL-17 signature genes in the BAE 
dataset (n=237). Signature genes shown in rows across participants in 
columns. Blue and red indicates low and high relative gene expression, 
respectively. Smokers with and without COPD are indicated by red and black 
in the above color bar, respectively. Clustering across participants and genes 
was done by Euclidean distance with average linkage.
Placebo




























































































































Figure 3. IL-17 blockade in psoriasis. Ixekizumab: The IL-17 signature was (A)
decreased in psoriatic skin lesions (n=6) after 2 weeks of Ixekizumab compared to
(B) placebo (n=4). Brodalumab: compared to (C) placebo (n=5), Brodalumab
(n=20) at a dose of (D) 140mg did not, but (E) 350mg (at 1 and 2 weeks) and (F)
700mg (at 2 and 6 weeks) did result in a decrease in the IL-17 signature,
consistent with clinical response. The IL-17 signature was higher in psoriatic


































Figure 4. The IL-17 gene signature in the BAE dataset (n=237) is (A) 
increased in former (0.29±0.46) compared to current smokers (-0.42±0.48, 
p<0.001 by Wilcoxon Rank Sum test), and (B) associated with decreasing




































































































 Figure 5. Airway neutrophils and macrophages. GLUCOLD (n=79): the 
IL-17 signature was associated with increasing log2 counts of (A) airway 
tissue neutrophils, (B) airway tissue macrophages, and (C) sputum 
neutrophils (n=72 with measured neutrophils). (D) SPIROMICS: the 
signature was associated with log2 sputum neutrophil counts (n=20). 






























Figure 6. CT Biomarkers. The IL-17 signature was associated with 
increasing percent of lung area with (A) functional small airways disease 
(PRMfsad) but not (B) emphysema (PRMemph) by parametric response 
mapping of baseline CT scans (n=35). P-values shown for linear models 
























































Figure 7. ICS response in GLUCOLD. An increased baseline IL-17 signature 
was associated with a greater decrease in percent change in FEV1 in the 
ICS ± long acting beta agonist group (n=33) compared to placebo (n=16) at 
30 months (p=0.024 for the linear model interaction with adjustment for age 
and smoking status). Participants with low IL-17 signatures were more likely 
to show an improvement in FEV1 after ICS (greater than zero: above the 





Table 1. Demographic characteristics of the three datasets.  
Means and (SD) or total counts are given for continuous and dichotomous variables respectively. For the BAE dataset 
p-values for differences between smokers with and without COPD by fischer’s exact test or t-test as appropriate are 
given. GLUCOLD and SPIROMICS included only COPD participants, and point values are shown for all baseline 
participants. For GLUCOLD differences between those randomized to placebo or inhaled corticosteroid and the 
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Age 65 (6) 64 (6)    0.22 61 (8) 58 (8) 61 (8) 0.22 63 (8) 
Smoking 
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Table 2. Association between IL-17 metric and cell counts or T2S score.  
 “Adjusted” models adjusted for smoking status and age. Count values for endobronchial tissue and sputum samples 
were logged prior to analysis. False discovery rates calculated on a cell type specific basis over each study. 





 Unadjusted Adjusted 
 R2 Coefficient 
(SE) 




   GLUCOLD  
       Endobronchial  
neutrophils 
 0.19   0.27 ( 0.06) 6.41*10-5 <0.001  0.20   0.26 (0.07)   0.0008 0.002 
       Sputum neutrophils  0.14   0.34 (0.10)   0.001  0.002  0.17   0.27 (0.13)   0.041 0.061 
       Blood neutrophils (%)  0.002  -0.83 (2.00)   0.68  0.68  0.08   0.57 (2.26)   0.80 0.80 
   SPIROMICS  
       Sputum neutrophils  0.14   0.33 (0.19)   0.10 0.20  0.37   0.44 (0.19)   0.033 0.066 
       Blood neutrophils  0.005  -0.02 (0.03)   0.63 0.63  0.09   0.03 (0.04)   0.43 0.43 
Macrophages 
    GLUCOLD 
       Endobronchial 
macrophages 
 0.13   0.22 (0.06)   0.0009 0.002  0.14   0.20 (0.07)   0.009 0.019 
       Sputum macrophages  0.008   0.07 (0.09)   0.45 0.45  0.03 -0.02 (0.11)   0.84 0.84 
    SPIROMICS 
       Sputum macrophages  0.008   0.05 (0.13)   0.71 N/A  0.02   0.06 (0.14)   0.68 N/A 
Eosinophils 
     GLUCOLD  
       Endobronchial 
eosinophils 
 0.02   0.11 (0.10)   0.28 0.35  0.01   0.02 (0.12)   0.87 0.923 
       Sputum eosinophils  0.01   0.09 (0.08)   0.31 0.35  0.05 -0.01 (0.11)   0.92 0.923 
       Blood eosinophils  0.01   0.32 (0.34)   0.35 0.35  0.10 -0.21 (0.39)   0.59 0.923 
     SPIROMICS  
       Sputum eosinophils  0.11   0.46 (0.40)   0.27 0.31  0.56   0.40 (0.41)   0.35 0.35 
       Blood eosinophils  0.02   0.07 (0.07)   0.31 0.31  0.07   0.12 (0.08)   0.15 0.30 
Mast Cells 
      GLUCOLD 
       Endobronchial  
mast cells 
 0.007  -0.03 (0.04)   0.47 N/A  0.01 -0.02 (0.05)   0.67 N/A 
T2S Score 
BAE  0.05 -1.49  (0.71)   0.039 N/A  0.10 -0.94 (0.85)   0.27 N/A 
GLUCOLD  0.04 -1.01  (0.60)   0.096 N/A  0.14 -0.16 (0.67)   0.82 N/A 
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Table 3. Association between IL-17 metric and clinical parameters in COPD participants.  
“Adjusted” models adjusted for smoking status and age. Abbreviations: SE= Standard Error, FEV1%Pred= Forced 
expiratory volume in one second percent predicited, PRMfSAD= parameteric response mapping functional small 
airways disease biomarker, PRMemph= parameteric response mapping emphysema biomarker, T2S= Type 2 





 Unadjusted Adjusted 
  R2 Coefficient 
(SEM) 




   BAE   
      FEV1 % Predicted 0.01   -2.34  (2.28)   0.31 N/A   0.09  -5.52  (2.68) 0.042  N/A 
GLUCOLD  
      FEV1 % Predicted 0.04   -3.40  (1.81)  0.064 N/A   0.07  -3.23  (2.10) 0.129  N/A 
SPIROMICS  
      FEV1 % Predicted≠ 0.03   -2.50  (2.1)  0.23 0.35   0.13  -5.24  (2.44)  0.038* 0.057 
      CT PRMemph≠ 0.03    0.61  (0.65)  0.35 0.35   0.08   0.78  (0.91)  0.40 0.40 
      CT PRMfSAD≠ 0.12    3.40  (1.57)  0.037 0.11  0.26   5.70  (2.07)  0.0097* 0.029 
Longitudinal  
   GLUCOLD:  Change over 30 months after Inhaled steroid treatment compared to 
placebo (n=48) 
 
      FEV1 % 0.23 -0.014 (0.009)   0.11 N/A  0.36 -0.019 (0.008)  0.024  N/A 
       FEV1 % also adjusted 
for airway tissue 
eosinophils 
N/A N/A    N/A N/A  0.36 -0.020 (0.009)  0.027  N/A 
      FEV1 % also adjusted 
for T2S score 
N/A N/A    N/A N/A  0.38 -0.020 (0.008)  0.018  N/A 
       FEV1 % also adjusted 
for airway tissue 
neutroophils 
N/A N/A    N/A N/A  0.3 -0.022 (0.009)  0.016 N/A 
       FEV1 % also adjusted 
for airway tissue 
macrophages 
N/A N/A    N/A N/A  0.36 -0.019 (0.008)  0.030 N/A 
